Home / Conferences

Conferences

Terrapinn World Biosimilar Congress 2017

World Biosimilar Congress 2017
31 October – 1 November 2017
Basel, Switzerland

DIA Biosimilars Conference 2017

DIA Biosimilars Conference 2017
24−25 October 2017
Hyatt Regency
Bethesda, MD, USA

AAM 2017 Fall Technical Conference

AAM 2017 Fall Technical Conference
6–8 November 2017
Bethesda North Marriott Hotel and Conference Center
North Bethesda, USA

SMi 4th Annual Biosimilars North America

4th annual Biosimilars North America
15–16 November 2017
Renaissance Woodbridge Hotel
Iselin, New Jersey, USA

Medicines for Europe 11th Pharmacovigilance Conference 2018

11th Pharmacovigilance Conference 2018
24 January 2018
The Landmark London Hotel
London, UK

European Pharmacopoeia prepares for the future through exchange with stakeholders

To mark the publication of the 9th edition of the European Pharmacopoeia (Ph. Eur.), the EDQM (European Directorate for the Quality of Medicines) organized a large international conference in Tallinn, Estonia, which brought together representatives of European and international regulatory authorities, the World Health Organization (WHO), pharmacopoeias from different continents as well as industry and associations from Europe and beyond. Participants came from 41 different countries, including Brazil, Canada, India, Japan, South Africa, Taiwan and USA.

Extrapolation key issue at European biosimilars conference

The European Generic medicines Association (EGA) held its 13th EGA-European Biosimilars Group Conference in London on 23–24 April 2015.

French generics association promotes biosimilars

French generics association GEMME held its first symposium on the challenges and opportunities associated with biosimilars in France on 3 October 2014.

Topics presented at the 16th IGPA conference on generics

Topics presented at the 16th Annual IGPA Conference, held in Brussels, Belgium, 9–11 December 2013, showed that despite differences in the pharmaceutical market in different countries most appreciate the value of generics. In most cases this is driven by cost reduction.

EGA pushes for increased focus on generics and biosimilars

EGA President Ms Gudbjorg Edda Eggertsdottir, speaking at the European Generic medicines Association’s (EGA’s) conferences in London, UK (11th EGA International Symposium on Biosimilar Medicines) and in Athens, Greece (19th EGA Annual Conference); stressed the importance of keeping generics and biosimilars manufacturers within Europe, thus ensuring that high quality manufacturing jobs and know-how remains in Europe. This would benefit society and patients and increase the competitiveness and innovative capacity of the pharmaceutical industry in Europe.